Rituximab associated necrosis: A case report.
BACKGROUND
Rituximab is a B-cell-depleting unconjugated monoclonal IgG1 antibody that targets the transmembrane protein CD20. This article reports on a case with the rare complication known as Rituximab-associated mucosal necrosis.


CASE PRESENTATION
The present case report addresses, for the first time, a patient affected by Devic's syndrome presenting with oral manifestations of palatal necrosis after rituximab treatment.


CONCLUSION
The present case raises the possibility of anti-CD20 antibody contributing to the development of palatal mucosal necrosis in some patients. Given the increasing administration of rituximab as a result of its efficacy against several diseases, a report on the potential iatrogenic effects of this drug is essential.
['Ashtari|Fereshteh|F|', 'Hakamifard|Atousa|A|', 'Hariri|Amirali|A|', 'Gholipour-Shahraki|Tahereh|T|']
D058846:Antibodies, Monoclonal, Murine-Derived D000970:Antineoplastic Agents D001402:B-Lymphocytes D005260:Female D006801:Humans D009336:Necrosis D009471:Neuromyelitis Optica D000069283:Rituximab
Rituximab Necrosis Devic's syndrome